RedHill Biopharma Completes Treatment of Last Patient with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study
  • Last patient has completed treatment course with RHB-105, for primary endpoint evaluation
  • The Phase III top-line results with RHB-105 for the treatment of H. pylori bacterial infection are expected during the third week of June 2015, subject to completion of review requirements
  • RHB-105 targets a significantly broader indication than current standard treatments for H. pylori , as a first-line treatment of  H. pylori  infection, regardless of ulcer status
  • RHB-105 was granted a QIDP designation by the FDA, allowing RedHill to benefit from fast-track development status for RHB-105, priority review, and extended market exclusivity for a total of 8 years
  • The 2015 global and U.S. markets for H. pylori eradication therapies were recently estimated at approximately $4.83 billion and $1.45 billion, respectively

TEL-AVIV, Israel, June 8, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (TASE: RDHL ) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that the last patient enrolled in the first Phase III study with RHB-105 for the treatment of Helicobacter pylori ( H. pylori ) bacterial infection has completed the treatment course with the investigational product, RHB-105, for primary endpoint evaluation. Top-line results from this study are expected in the third week of June 2015, subject to completion of review requirements.

The randomized, placebo-controlled, Phase III study (the ERADICATE Hp study) is intended to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed  H. pylori  bacterial infection, a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa associated lymphoid tissue (MALT) lymphoma. If successful, the ERADICATE Hp Phase III study is planned to be followed by a second Phase III study and additional studies may be required, subject to FDA feedback. A total of 118 non-investigated dyspepsia patients with confirmed  H. pylori  infection were enrolled and treated in the ERADICATE Hp study, which was conducted in the U.S. Subjects were randomized in a 2:1 ratio to receive either RHB-105 or a placebo for a period of 14 days and assessed for the eradication of  H. pylori  infection 28 to 35 days after completion of treatment. The primary endpoint of the study is to show superiority in eradication of  H. pylori  infection over historical standard of care efficacy levels of 70% effectiveness.

With RHB-105, RedHill is pursuing an indication of first line treatment of  H. pylori  infection regardless of ulcer status, a significantly broader indication than current standard treatments for H. pylori , which are typically limited and indicated to treat patients with an active or recent history of ulcers. If approved, RHB-105 may be the first  H. pylori  eradication therapy to target this broader indication, which would significantly expand the potential patient population on the label for this drug candidate.

RHB-105 was designated by the FDA as a Qualified Infectious Disease Product (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act, which is intended to incentivize the development of new antibiotic drugs for the treatment of serious or life-threatening infections. The designation allows RedHill to benefit from fast-track development status for RHB-105, providing for an expedited development pathway, as well as priority review status, potentially leading to a shorter review time by the FDA of a New Drug Application (NDA), if filed. If approved, RHB-105 will also receive an additional five years of U.S. market exclusivity in addition to the standard exclusivity period, for a total of 8 years of market exclusivity.   

The 2015 global and U.S. market potential for H. pylori eradication therapies, at current branded prices, was recently estimated at approximately $4.83 billion and $1.45 billion, respectively, and could potentially grow with increasing awareness of the health risks associated with H. pylori infection and the benefits of its eradication 1 .

About RHB-105:

RHB-105 is a new and proprietary fixed-dose oral combination therapy of two antibiotics and a proton pump inhibitor (PPI) in an all-in-one oral capsule with a planned indication for the treatment of  H. pylori  infection.  H. pylori  bacterial infection is a major cause of chronic gastritis, peptic ulcer disease, gastric cancer, and mucosa associated lymphoid tissue (MALT) lymphoma. RHB-105 is currently undergoing a first Phase III clinical study in the U.S. (named ERADICATE Hp), planned to be followed, if successful, by a second Phase III study. Additional studies may be required, subject to FDA feedback. RHB-105 has been granted Qualifying Infectious Disease Product (QIDP) designation by the FDA, providing a fast-track development pathway, as well as priority review status, potentially leading to a shorter review time by the FDA of an NDA, if filed. If approved, RHB-105 will also receive an additional five years of U.S. market exclusivity, on top of the standard exclusivity period, for a total of 8 years of market exclusivity.  

About RedHill Biopharma Ltd.:

RedHill Biopharma Ltd. (Nasdaq: RDHL ) (TASE: RDHL ) is an emerging Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. RedHill's current pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection, with an ongoing first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease, with an ongoing first Phase III study; (iii) BEKINDA ™ (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted in December 2014; (iv) RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) ABC294640 – a Phase II-stage orally-administered SK2 inhibitor targeting multiple inflammatory-GI diseases and related oncology indications; (vi) MESUPRON ® - a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; (vii) RP101 - currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (viii) RIZAPORT ™ (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA currently under discussions with the FDA and a European marketing application submitted in October 2014; and (ix) RHB-101 - a once-daily oral pill formulation of the cardio drug carvedilol.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates; (v) the Company's ability to establish and maintain corporate collaborations; (vi) the interpretation of the properties and characteristics of the Company's therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (vii) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (ix) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (x) estimates of the Company's expenses, future revenues capital requirements and the Company's needs for additional financing (xi) competitive companies and technologies within the Company's industry; and (xii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 26, 2015. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.

1 Jerry Rosenblatt, Ph.D., a member of RedHill's Advisory Board and Partner at Foster Rosenblatt, RedHill Biopharma press release: RedHill Biopharma's Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market , May 18, 2015. 

Company contact: Adi Frish Senior VP Business Development & Licensing RedHill Biopharma +972-54-6543-112 IR contact (U.S.): Marcy Nanus Senior Vice President The Trout Group +1-646-378-2927

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 151

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 109

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 43

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 16

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 21

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 17

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 24

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 362

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating a Milestone: Gifting the 400th Home to a Veteran

Updated Category News Views 339

Celebrating a Milestone with 400th Home Gift Building Homes for Heroes and Hillwood Properties proudly partnered to celebrate a significant milestone by gifting a home to U.S. Army Specialist Joshua Sager and his family. This remarkable achievement signifies the organization’s commitment to providing veterans and first responders with the means to establish a fresh...

Continue Reading
Wheeler REIT Achieves Record Price as Growth Continues

Updated Category News Views 259

Wheeler REIT Reaches New Milestone In an extraordinary demonstration of resilience and upward momentum, Wheeler Real Estate Investment Trust (WHLRD) has achieved a remarkable milestone by hitting a 52-week high of $27.49 USD. This achievement reflects the company's strong performance and investor confidence in its strategic direction. Strong Financial Position Recent data...

Continue Reading
S&P Global Splits Off Mobility Unit: Investor View

Updated Category News Views 52

Strategic Moves Shake Up S&P Global Listen up, traders! You don’t want to miss what S&P Global, ticker NYSE:SPGI, is cooking up. They've given the green light to split off their Mobility division, officially birthing Mobility Global Inc. This shake-up promises to stir some excitement in the market. Buckle up, because here's what this movement means for you and your...

Continue Reading
Carvana's Q3 Earnings Surge Promises Bright Future for CVNA

Updated Category News Views 103

Carvana Shares Soar After Impressive Q3 Earnings Report Recently, Carvana (NYSE: CVNA), a leading online used-car retailer, experienced a significant surge in its stock price as a result of a positive earnings announcement for the third quarter. The encouraging outlook provided by the company has delighted investors, pushing shares upward during premarket trading....

Continue Reading
PHINIA Unveils Comprehensive Guide to International Emission Standards

Updated Category News Views 150

PHINIA Unveils New Emission Standards Guide for 2024/25 PHINIA Inc. (NYSE: PHIN), a leading name in premium fuel systems and electrical solutions, has launched its latest 2024/25 Emission Standards Booklet specifically designed for heavy-duty and off-road vehicles, engines, and machinery. This guide is unique as it serves as the only complete resource available to keep...

Continue Reading